Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index

Haring, Liina; Koido, Kati; Vasar, Veiko; Leping, Vambola; Zilmer, Kersti; Zilmer, Mihkel; Vasar, Eero

doi:10.1016/j.schres.2015.08.027

Cited by 56 publications

(80 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the above reported evidence, little is known regarding the relationship between inflammation and meta- we have demonstrated that antipsychotic-naïve FEP patients had significantly elevated levels of epidermal growth factor (EGF), interleukin-4 (IL-4) and IL-6 and reduced level of IL-1β compared to CS. Furthermore, 7 months of antipsychotic drug treatment reduced significantly levels of EGF, vascular endothelial growth factor (VEGF), interferon-γ (INF-γ), IL-2, IL-4, IL-6, IL-8 and IL-1α in these patients compared to the premedication levels of these markers, and elevated body mass index (BMI) (Haring et al, 2015). To elaborate our previous results and to establish the concurrent impact of antipsychotic treatment on inflammatory and metabolic biomarkers as well as BMI, we implemented alternative biochip array technology, which allowed to perform simultaneous assessment of metabolic and inflammatory biomarkers on the same cohort.…”

Section: Introductionmentioning

confidence: 99%

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study

Balõtšev

Haring

Koido

et al. 2017

Early Intervention Psych

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study

Balõtšev

Haring

Koido

et al. 2017

Early Intervention Psych

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of the 61 included studies, a total of 41 studies reported complete results on weight change and variability of weight change (SE or SD) for both sex subgroups (172 records in the meta‐analysis data). Twenty‐seven studies reported on olanzapine, risperidone or no medication and were used in the present meta‐analysis . However, only olanzapine, risperidone and no‐medication/placebo could be analysed (Tables a–c, 26 studies, 35 records).…”

Section: Resultsmentioning

confidence: 99%

No differences in olanzapine‐ and risperidone‐related weight gain between women and men: a meta‐analysis of short‐ and middle‐term treatment

Schoretsanitis

Drukker

et al. 2018

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Futamura et al 18 reported significantly decreased serum EGF concentrations in antipsychotic-free patients and in the antipsychotic-naive patients with schizophrenia. Recently, Haring et al 20 reported that serum levels of EGF were increased in FEP patients, but after for approximately 7 months antipsychotic medication treatment, EGF levels decrease and are related to the clinical improvement of FEP patients. It is well known that EGF protects dopaminergic neurons from glutamate toxicity in culture 6,16,29,30 .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, investigators who examined the relationship between peripheral EGF levels and the psychopathology of patients with schizophrenia 8,18,20 yielded conflicting results. A survey conducted by Futamura et al 18 revealed a significant decrease in serum EGF levels in the patient sample (i.e., 4 medication-naive and 45 medicated chronic schizophrenia patients) relative to healthy controls.…”

mentioning

confidence: 99%

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

Zhang

Xiao

Chen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

previous studies have demonstrated that neurotrophic factors may play a critical role in the severity of clinical symptoms in schizophrenia. However, it remains unknown whether serum levels of epidermal growth factor (eGf) in schizophrenia are similar to those observed in the case of other neurotrophic factors. Therefore, we compared serum EGF concentrations in first-episode drug-naive (FEP) patients and medicated chronic schizophrenic patients with healthy controls in order to explore whether eGf levels are related to psychopathological symptoms. We measured the serum levels of EGF in 78 firstepisode medication-naive schizophrenia patients, 76 medicated chronic schizophrenic patients, and 75 healthy controls using the sandwich eLiSA method. Disease severity were measured using the positive and negative syndrome scale (PANSS). Serum EGF levels showed a significant decrease in schizophrenia patients in comparison to healthy subjects. Serum eGf levels in fep patients are indistinguishable from chronic cases. eGf levels were related to pAnSS general symptom subscales in both fep nevermedicated and medicated patients. it is interesting that serum eGf levels were negatively correlated with the PANSS cognitive subscales, with the exception of the patients with chronic schizophrenia. our preliminary results indicated that eGf may play a role in this illness and that it could be used as a potential biomarker of disease severity. Moreover, EGF may be associated with cognitive subscales of pAnSS in fep patients. future studies should investigate the relationship between eGf and cognitive function as measured using standardized neuropsychological assessments to identify potential biomarkers related with cognition.Epidermal growth factor (EGF), which was isolated from the submandibular gland of male mice by Stanley Cohen in 1962, is a very important neurotrophic factor, and is closely related to the proliferation, growth, differentiation, and regeneration of the central nervous system cell 1 . EGF exerts many biological functions by binding to its receptor EGFR and increasing Ca2+ concentration and the pH value in intracellular, which provides the necessary conditions for DNA synthesis and cell division 2,3 . Animal experiments showed that EGF could promote the growth of hippocampal neurons in vitro and enhance the activity of succinate dehydrogenase in neural stem cells 3-5 . In addition, EGF is a broad-spectrum neurotrophic factor which can ensure the survival of neurons, protect dopaminergic neurons from glutamate toxicity 6 , and repair neurons in the case of pathological conditions 2 , which is implicated in the repair process following brain injury.There is evidence that EGF levels are associated with the pathogenesis of schizophrenia 7-12 . Genetic studies revealed a significant association between EGF gene polymorphism and premorbid and current cognitive functioning or the age of onset of schizophrenia [13][14][15] . In addition, peripheral transcription of NRG-ErbB pathway genes are upregulated in the case of treatm...

show abstract

Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index

Cited by 56 publications

References 29 publications

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study

No differences in olanzapine‐ and risperidone‐related weight gain between women and men: a meta‐analysis of short‐ and middle‐term treatment

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

Contact Info

Product

Resources

About